Not yet recruitingInterventionalPhase 1Last updated Aug 11, 2026

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

Overview

ClinicalTrials.gov ID: NCT07758231
Lead Sponsor: University of Wisconsin, MadisonOTHER
Brief Summary: This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Study Type: Interventional

Secondary IDs

Protocol Version 7/20/26Other Identifier

UW Madison

Pharmacy | Pharmacy PracticeOther Identifier

UW Madison

ICTR TBCR Pilot AwardOther Identifier

UW Madison

Status

Study Record Dates

NCT06994338Recruiting

Tirzepatide for Alcohol Use Disorder

NCT03232112Completed

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

NCT06939088Recruiting

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

NCT03645408Terminated

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

NCT02311686Completed

Non-oxidative Metabolite Profiles After Increasing Doses of Ethanol

NCT06546384Not yet recruiting

GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease